Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LB-208 in advanced solid tumors and lymphoma
NCT07914348Phase 1Recruiting
- Sponsor
- Leukos Biotech
- Start
- Aug 2024
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AOP208 in solid tumor and lymphoma, sponsored by Leukos Biotech. Primary endpoints: Incidence of Treatment related Adverse events up to 18 months and Maximum Tolerated Dose up to 18 months. Started Aug 2024; status: recruiting.
02
Drugs
AOP208
03
Conditions
solid tumorlymphoma
Beyond the preview
Go deeper on NCT07914348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07914348.